Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + fluorouracil + calcium levofolinate
- Development stage
- Phase 2
- Lead developer
- Fujian Medical University Cancer Hospital
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
FOLFPTX is an investigational chemotherapy combination regimen consisting of paclitaxel, fluorouracil (5-FU), and calcium levofolinate (leucovorin). It is being evaluated by Fujian Cancer Hospital as a first-line treatment for patients with advanced gastric cancer (AGC) or adenocarcinoma of the esophagogastric junction (AEG). Within this regimen, paclitaxel acts as a microtubule stabilizer that interferes with cell division by preventing the depolymerization of tubulin. Fluorouracil is an antimetabolite that inhibits thymidylate synthase and is incorporated into DNA and RNA, thereby disrupting nucleic acid synthesis. Calcium levofolinate is included as a biochemical modulator to enhance the cytotoxic activity of fluorouracil. This triplet regimen is being compared against standard doublets like mFOLFOX and mFOLFIRI in randomized clinical trials (such as NCT03045770) to determine its relative efficacy and safety profile in the first-line setting.
- Other names
- Paclitaxel-Fluorouracil-Calcium Levofolinate combination
02
Targets
TS (Thymidylate synthase)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on paclitaxel + fluorouracil + calcium levofolinate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + fluorouracil + calcium levofolinate.